Canadian Coast Guard begins 2025 Arctic Summer Season
YELLOWKNIFE, NT, June 20, 2025 /CNW/ - The Canadian Coast Guard's annual Arctic summer operational season is underway. Through its new Arctic Strategy, the Canadian Coast Guard is working with Inuit, First Nation, and Métis partners to deliver services and programs in the North, by the North, for the North.
In total, seven Canadian Coast Guard icebreakers are scheduled to deploy from June into November to enable the annual northern community resupply, search and rescue operations, marine pollution incidents, Canadian Arctic security, and other operational and program commitments.
June 11 – CCGS Pierre Radisson departed Quebec City, QC, for icebreaking, Arctic science support, Marine Environmental and Hazards Response (MEHR) vessel reconnaissance and assessment, buoy tending operations, and refueling Killiniq's remote communication station.
June 26 – CCGS Henry Larsen departs St. John's, NL, for icebreaking, Arctic science support, and Operation Pacer Goos e – to support the annual resupply of U.S. Pituffik Space Base in Greenland.
June 27 – CCGS Amundsen departs Quebec City, QC, for the 2025 Amundsen Science mission.
July 1 – CCGS Des Groseilliers departs Quebec City, QC, for icebreaking, Arctic science support, MEHR vessel reconnaissance and assessment, and refueling the weather station in Eureka, NU.
July 9 – CCGS Jean Goodwill departs Dartmouth, NS, for icebreaking in Southern and Central Arctic, as well as the High Arctic, if required.
July 17 – CCGS Sir Wilfrid Laurier departs Nome, Alaska (following its deployment in Operation North Pacific Guard), for icebreaking, Arctic science support, MEHR vessel reconnaissance and assessment, and buoy tending operations in the Western Arctic.
September 18 – CCGS Louis S. St-Laurent departs Cambridge Bay, NU, to assist the Joint Ocean Ice Study in the Beaufort Sea, and provide icebreaking support in the High and Low Arctic. It will be the last vessel operating in the Arctic, until the end of November 2025.
Through presence, assistance, and operations, the Canadian Coast Guard continues to demonstrate and reinforce Canada's long-standing, well-established sovereignty in the North.
Quick Facts:
The Canadian Coast Guard maintains safe and efficient marine navigation in Arctic waters by providing icebreaking services to the shipping industry and other vessel traffic, and daily ice and operations briefings in the North.
Iqaluit's Marine Communications and Traffic Services centre reopened on May 16, 2025, and ensures safe navigation in the region by monitoring Arctic marine traffic, responding to maritime distress calls, broadcasting weather and ice information, and issuing navigational warnings.
Across the Arctic, search and rescue training occurs with Canadian Coast Guard Auxiliary units to gain extensive local knowledge of specific risks and enhance capacity for search and rescue in the Arctic.
The seasonal Arctic Marine Response Station in Rankin Inlet, NU, will reopen on June 25, 2025, to provide local maritime search and rescue services during the summer season.
The Arctic MEHR and Monitoring and Compliance teams maintain a permanent presence in the Arctic, with a network of 28 equipment caches, 24/7 standby response for marine pollution incidents in the North, and full-time facilities in Iqaluit, NU, and Yellowknife and Hay River, NT.
On Great Slave Lake and the Mackenzie River in the Northwest Territories, the Canadian Coast Guard's two specialized buoy tenders, the CCGS Dumit and CCGS Eckaloo, conduct seasonal buoy tending to help commercial shipping and community resupply along the river, if water levels permit.
SOURCE Canadian Coast Guard
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
38 minutes ago
- Cision Canada
Asteroid Day Gains Momentum with U.S. Recognition from Flagstaff, Coconino County, U.S. Senate, and Vera C. Rubin Observatory Data Release
LUXEMBOURG, June 25, 2025 /CNW/ -- The Asteroid Foundation, working in collaboration with B612 Foundation, founding sponsor of Asteroid Day, is proud to announce significant advancements in the global recognition of June 30th as Asteroid Day. Following the United Nations' historic designation of the date as International Asteroid Day in 2016, local and national governments in the United States are now joining in to formally recognize this important awareness initiative. Since its inception, hundreds of independently organized Asteroid Day events have been taking place globally, calling attention to the critical need for awareness of both the dangers and possibilities associated with asteroids. This year, the movement celebrates official recognition from Flagstaff, Arizona, Coconino County, Arizona, and the United States Senate, marking a pivotal moment in bringing asteroid awareness to the forefront of public consciousness in the USA. Notably, these local, city, and national recognitions are the first in the world to highlight the profound importance of Asteroid Day in inspiring the next generation through Science, Technology, Engineering, Arts, and Mathematics (STEAM) activities. "As a retired astronaut, I know firsthand the importance of space research. Asteroid Day is a critical initiative that not only raises awareness about planetary defense but also ignites curiosity and inspires the next generation of scientists, engineers, and explorers to pursue careers in STEAM. I'm proud to introduce a resolution recognizing Asteroid Day in the United States Senate," said retired astronaut and U.S. Senator Mark Kelly (D-AZ). The Senate resolution was introduced in partnership with U.S. Senator John Cornyn (R-TX). "B612 Foundation, as the founding sponsor of Asteroid Day and a leading voice in asteroid analysis and mapping and planetary defense, championed the development of the 100x Declaration, a call to action that launched the global Asteroid Day movement. 'We are humbled and excited to see that in addition to the United Nations recognizing Asteroid Day on 6 December 2016, both Arizona and the United States government are now following suit,' said Danica Remy, Asteroid Day Co-founder and President of B612. 'I am additionally delighted that the US National Science Foundation and Department of Energy Vera Rubin Observatory is using Asteroid Day to release its first data product for scientists and the public. This growing momentum highlights the critical importance of understanding asteroid risks and opportunities for humanity's future." "This global movement would not have been possible without the visionary leadership of the Government of Luxembourg, particularly the contributions of former Deputy Prime Minister Etienne Schneider, today's CEO of Luxembourg's state innovation agency Luxinnovation Mario Grotz, and today's CEO of Luxembourg Space Agency (LSA) Marc Serres. Their efforts, alongside former NASA Ames Director Pete Worden and former Consul General and Executive Director Luxembourg Trade & Investment San Francisco Georges Schmit, as well as the dedicated leadership of the Asteroid Foundation board of directors, have amplified the Asteroid Day program globally," said Markus Payer, Chair of Asteroid Foundation. "The Luxembourg government's invitation to Asteroid Day co-founders, Apollo 9 astronaut Rusty Schweickart, Danica Remy, Grig Richters and Dr. Brian May, to establish the Asteroid Foundation in Luxembourg in 2017 provided the essential groundwork. This commitment was further solidified by the ongoing leadership of the LSA, which has played an instrumental role in supporting Asteroid Day's global program, alongside Luxembourg's rich local and cross-European in-person year-round initiatives." Asteroid Day serves as a global platform to educate the public about the exciting prospects of asteroid resource utilization and their role in understanding the origins of our universe, while also covering the role of asteroids in our solar system and the science and technology being developed to detect, track, and ultimately mitigate potential threats. About Asteroid Foundation: A Luxembourg based nonprofit, founded 2017, is the home of Asteroid Day and is dedicated to promoting public awareness and education about asteroids and space. Through global events, educational initiatives, and strategic partnerships, the Foundation strives to inspire a greater understanding of asteroids and their significance to our planet and humanity's future in space. For more information, visit or follow on social: Facebook, LinkedIn or Instagram.
Cision Canada
9 hours ago
- Cision Canada
FFC Launches Two Major Publications for Fusion Fuel Cycle Development
As work continues on the installation of world's first fully-integrated fuel cycle, public-private-partnership FFC shares details on underlying model and design philosophy. CHALK RIVER, ON, June 25, 2025 /CNW/ - Fusion Fuel Cycles Inc. (FFC), a joint venture between Canadian Nuclear Laboratories and Kyoto Fusioneering, is pleased to announce that it has recently published two foundational papers for the company: "The Fusion Fuel Cycle Simulator — towards integrated dynamic process simulation of fusion fuel cycles" and "Conceptual Design of UNITY-2, the Fuel Cycle Test Facility for Fusion Pilot Plants." The fuel cycle is an essential part of any proposed commercial fusion power plant design – breeding, capturing, extracting, and recycling the precious tritium required for fusion reactions to take place is the only way to achieve fusion's promise of limitless clean energy. FFC's mission is to close this technology gap for fusion developers and believes that these papers represent a key milestone in accomplishing that mission. An accurate, reliable model is an indispensable tool for designing complex integrated systems. In the case of fusion fuel cycles, the performance of individual sub-systems is often reliant on the status of the other components, making the problem inherently dynamic. FFC's solution was to develop a new model to meet their design needs: The Fusion Fuel Cycle Simulator (FFCS im). "FFC Sim is a new, modular and flexible tool for fusion fuel cycle simulation and design. It can be exploited for dynamic, physics-based and closed-loop simulations of holistic fuel cycle layouts with a particular emphasis on managing tritium streams and inventories." Notes Dr. Christian Day – FFC's Chief Technology Officer. "We were particularly concerned with the need for testing and comparing different fuel cycle configurations to find the most efficient combinations for our customers' use cases. For that reason, we used a modular design for the tool to enable quantitative prediction of individual unit performance." FFC is also making progress in the realm of physical equipment. Design and construction efforts are underway on the "Unique Integrated Testing Facility" (UNITY-2), the world's first fully-integrated fusion fuel cycle system to be built in at the Chalk River site, managed by Canadian Nuclear Laboratories' (CNL). With commissioning planned to begin in 2026, the team have recently published a paper describing the facility and its systems in detail. Dr. Sam Suppiah – Chief Scientific Officer of FFC emphasized the importance of this project: "FFC recognized that meeting the needs of the rapidly advancing private fusion industry would require a much more aggressive development of fuel cycle technology. For that reason, we are pushing hard to commission UNITY-2 as soon as possible to provide industry, academia, and publicly funded fusion programs with the data and testing capabilities they need to bring this promising clean-energy technology to market. I encourage anyone interested to read this paper and to reach out to our team as we plan the first few years of our testing program." To view the papers, please visit the following links: Link to UNITY-2 paper: About FFC FFC is a joint venture between two of the world's leading fusion service providers – Canadian Nuclear Laboratories (CNL) and Kyoto Fusioneering (KF). Founded in 2024, FFC combines over 70 years of tritium research and management expertise with the nimble, customer-focused approach of a start-up. At Fusion Fuel Cycles Inc. (FFC), we provide end-to-end solutions to delivering a performance-driven fuel cycle. From design to full operations, our fuel cycle systems are designed to boost fuel efficiency, reduce tritium inventory, and maximize heat transfer for power conversion—enabling safe, high-performance, and cost-effective fusion energy systems. FFC is committed to support the development of the fusion ecosystem and is gladly engaged in consultations that pertain to our areas of expertise such as tritium management, handling and operational experience.
Cision Canada
a day ago
- Cision Canada
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /CNW/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Indaptus Therapeutics, Inc. (NASDAQ: INDP), Perspective Therapeutics, Inc. (NYSE-American: CATX), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), and Autolus Therapeutics plc (NASDAQ: AUTL). Analysts at Nova One Advisor are currently projecting the global oncology drug market to hit US$366.24 billion by 2034, expanding at a 7.4% CAGR. Others are even more optimistic, with ResearchAndMarkets estimating the sector will reach US$866.1 billion by 2034, growing at a 10.8% CAGR, and Vision Research Reports anticipating the market will top US$903.81 billion by the same year, driven by accelerating demand for advanced diagnostics and treatments. All this points to an optimal timing period for breakout cancer stocks. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. In other recent industry developments and happenings in the market include: Indaptus Therapeutics, Inc. (NASDAQ: INDP) recently initiated dosing in a Phase 1b/2 study arm testing its lead candidate Decoy20 with PD-1 inhibitor tislelizumab in advanced solid tumors. "This is an important milestone in our clinical development," said Jeffrey Meckler, CEO of Indaptus. "We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors." The combination is being evaluated in patients previously treated with checkpoint inhibitors or with tumor types typically unresponsive to immunotherapy. Early preclinical findings showed Decoy20 could synergize with PD-1 blockade to activate stronger anti-tumor immunity. The trial will monitor safety and preliminary signals of efficacy before broader enrollment. Perspective Therapeutics, Inc. (NYSE-American: CATX) has recently opened enrollment for Cohort 3 of its Phase 1/2a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors. "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." The newly approved dose level represents a 20% increase over the previous cohort and will be evaluated for safety and early signals of efficacy. Interim results presented at American Society of Clinical Oncology (ASCO) Annual Meeting and Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting showed evidence of anti-tumor activity and favorable tolerability at lower doses. The company expects to submit additional clinical updates in the second half of 2025 following extended patient follow-up. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recently presented new preclinical data at the 2025 ASCO Annual Meeting showing that its CDK9 inhibitor SLS009 demonstrated potent activity in ASXL1-mutated colorectal cancer cell lines. "These results provide strong rationale for continued advancement of SLS009 as a potential treatment for ASXL1-mutated cancers," said Dr. Dragan Cicic, Senior Vice President, Chief Development Officer at SELLAS. "The ability to selectively target ASXL1-driven tumors at concentrations well below the known safety threshold opens the door for tolerable and effective therapy. Based on the findings, we believe that ASXL1 mutation status could serve as a potential biomarker for response to SLS009 inhibition, which may allow us to further refine patient selection and improve outcomes. We look forward to presenting these results at ASCO." In the study, 75% of lines with ASXL1 frameshift mutations responded at low nanomolar concentrations, while no response was observed in wild-type lines. These findings suggest that ASXL1 mutation status may serve as a potential biomarker for patient selection. Autolus Therapeutics plc (NASDAQ: AUTL) has released updated results from its FELIX study, showing that obe-cel, a next-generation CAR T cell therapy, may provide long-term remission for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). With a median follow-up of nearly 33 months, more than 50% of patients were still in remission at 24 months, and 38% had not needed any additional therapy. "Obe-cel's durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut," said Dr. Christian Itin, CEO of Autolus. "A well-tolerated, effective, durable treatment option for ALL patients who often have a poor prognosis and have had multiple prior treatments is of significant clinical benefit." The data suggested obe-cel could serve as a standalone option for some patients, reducing the need for transplants or further treatment. The company also reported a strong safety profile and plans to continue advancing obe-cel as a potential cornerstone in adult B-ALL care. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
